Thanks to the continued support of our donors, partners and community, Icon Cancer Foundation (ICF) has built strong momentum in our research program – momentum we are proud to carry forward into 2026.
At ICF, our research goes beyond the laboratory to the people who need it most.
With the continued support of our donors, we are helping to shape a future where cancer care is more targeted, more effective and more patient-centred.
Together, we are turning research into impact – in 2026 and beyond.
Our research program
At ICF, we support independent, clinician-led clinical trials and research projects guided by the doctors, nurses, radiation therapists and healthcare teams who care for patients every day across Icon Cancer Centre sites in Australia.
We focus our funding on the areas that matter most to our patients. From slowing disease progression to reducing treatment side effects, our research is designed to deliver real-world impact, ensuring innovation reaches the people who need it most.
In 2026, we will continue expanding our research impact, investing in projects and clinical trials which advance cancer care, bring new treatments closer to patients and support the next generation of therapies.
This year, our research priorities include:
▶ Advancing prostate cancer research
We are supporting research into highly targeted radiation techniques designed to delay the need for more aggressive treatments, while reducing side effects and improving quality of life for patients with advanced prostate cancer.
▶ Expanding theranostics
With the opening of Icon’s new specialist centre in Western Australia, we are well positioned to support new clinical trials in theranostics – a promising area of oncology which combines advanced imaging and targeted therapy to deliver more personalised treatment options.
▶ Strengthening investigator-led radiation trials
Radiation therapy remains central to most cancer treatments but receives limited commercial funding for clinical trials. Through Icon’s national radiation oncology network, our clinician-led trials explore innovative ways to combine radiation with other therapies across multiple cancer types, helping to refine and improve treatment approaches.
▶ Investing in cellular therapy and blood cancer research
Building on Icon’s longstanding expertise in stem cell therapy, ICF is investing in the next generation of cellular therapies and clinical trials for blood cancers by expanding infrastructure and supporting more clinical positions. This approach strengthens our research capabilities while providing additional care to our patients.
Your support has the power to accelerate our clinical trials and research in Australia, making a difference to patients now and a lasting impact for future generations.
Help us make a difference.